



CENTER FOR MEDICARE

DATE: April 20, 2026

TO: Medicare Advantage & Prescription Drug Plan Sponsors

FROM: Lara Strawbridge, Acting Director
Medicare Drug Rebate and Negotiations Group

SUBJECT: Removal of Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill from the Selected Drug List Effective January 1, 2027

In accordance with section 1192(c)(1) of the Social Security Act (“the Act”) and section 70 of the Medicare Drug Price Negotiation Program: Revised Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2026 (“Revised Guidance”), the following selected drug(s) will cease to be a selected drug on January 1, 2027 and the agreed-upon maximum fair price will cease to apply on January 1, 2027:

- Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill

In accordance with section 70 of the Revised Guidance, CMS determined that, for the selected drug(s) listed above, the totality of circumstances reveals that at least one biosimilar biological product licensed under 351(k) of the Public Health Service Act that identifies the selected drug as its reference product, is being bona fide marketed pursuant to such licensure.

In accordance with section 1192(c)(1) of the Act and section 70 of the Revised Guidance, because CMS made this determination after August 1, 2024, and before April 1, 2026, the selected drug listed above will remain a selected drug through 2026 and the agreed-upon maximum fair price will apply through December 31, 2026. The selected drug(s) will cease to be a selected drug on January 1, 2027, and the agreed-upon maximum fair price will cease to apply on January 1, 2027.

For questions, please contact IRARebateandNegotiation@cms.hhs.gov.